Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$701,222
in 5 filings, $701K under 10b5-1 plans

Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-05-03 Gibson Christopher Chief Executive Officer Gift −1,338 955,048
2023-05-03 Gibson Christopher Chief Executive Officer Exercise or conversion +31,250 $2.48 $78K 986,298
2023-05-03 Gibson Christopher Chief Executive Officer Sale −33,073 $4.71 $156K 953,225
2023-05-03 Gibson Christopher Chief Executive Officer Conversion +4,000 4,000
2023-05-03 Gibson Christopher Chief Executive Officer Sale −4,000 $4.91 $20K 0
2023-05-03 Gibson Christopher Chief Executive Officer Conversion +20,000 20,000
2023-05-03 Gibson Christopher Chief Executive Officer Sale −20,000 $4.90 $98K 0
2023-05-03 Gibson Christopher Chief Executive Officer Conversion +1,000 1,000
2023-05-03 Gibson Christopher Chief Executive Officer Sale −1,000 $4.92 $5K 0
2023-05-03 Gibson Christopher Chief Executive Officer Exercise or conversion · Stock Option (Right to Buy) −31,250 625,000
2023-05-03 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −1,338 6,551,496
2023-05-03 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −4,000 531,000
2023-05-03 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −20,000 488,000
2023-05-03 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −1,000 122,875
2023-04-21 Li Dean Y Director Gift −627,705 0
2023-04-03 Dar Zavain Director Grant or award +1,996 57,569
2023-03-02 Gibson Christopher Chief Executive Officer Conversion +3,000 966,710
2023-03-02 Gibson Christopher Chief Executive Officer Gift −3,000 963,710
2023-03-02 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −3,000 6,552,834
2023-02-02 Gibson Christopher Chief Executive Officer Conversion +3,000 966,710

Page 40 of 41 · 805 trades